Hidradenitis Suppurativa Tunnels: Unveiling a Unique Disease Entity

Overview

Journal JID Innov

Specialty Dermatology

Date 2025 Mar 4

PMID 40034103

Authors

Nicole Vecin

Nathan C Balukoff

Marita Yaghi

Tammy Gonzalez

Andrew P Sawaya

Natasa Strbo

Marjana Tomic-Canic

Hadar Lev-Tov

Irena Pastar

Affiliations

Soon will be listed here.

Abstract

Hidradenitis suppurativa tunnel structures lined with epithelium within the dermis are unique features of advanced disease stages that significantly impair patients' QOL. The presence of hidradenitis suppurativa tunnels is associated with a decreased likelihood of achieving a clinical response, even when receiving biological therapy. The cellular and molecular mechanisms underlying tunnel formation and pathology are only partially understood, which hampers the development of more effective targeted therapies. Tunnels create a unique microenvironment that drives a vicious cycle of hidradenitis suppurativa inflammation, with tunnel keratinocytes exhibiting an activated phenotype characterized by distinct gene expression signatures. In this review, we summarize the current literature and discuss aspects of the pathophysiology of tunnels, including the role of hair follicle epidermal stem cells in tunnel formation, potential role of fibroblast-mediated epithelial-mesenchymal transition, role of dermal papilla fibroblasts, and aberrant proinflammatory repair response contributing to the observed fibrosis and scarring. Finally, tunnel structures are characterized by unique microbial dysbiosis and an overabundance of Gram-negative anaerobes that are not targeted by current therapeutics. In addition to outlining the possible mechanisms of tunnel formation, we provide perspectives on the translation of current knowledge into more effective treatment approaches for patients with hidradenitis suppurativa tunnels.

References

Chopra D, Arens R, Amornpairoj W, Lowes M, Tomic-Canic M, Strbo N . Innate immunity and microbial dysbiosis in hidradenitis suppurativa - vicious cycle of chronic inflammation. Front Immunol. 2022; 13:960488. PMC: 9368759. DOI: 10.3389/fimmu.2022.960488. View

Sabat R, Simaite D, Gudjonsson J, Brembach T, Witte K, Krause T . Neutrophilic granulocyte-derived B-cell activating factor supports B cells in skin lesions in hidradenitis suppurativa. J Allergy Clin Immunol. 2022; 151(4):1015-1026. DOI: 10.1016/j.jaci.2022.10.034. View

Garg A, Neuren E, Cha D, Kirby J, Ingram J, Jemec G . Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2019; 82(2):366-376. DOI: 10.1016/j.jaad.2019.06.1301. View

Ma Y, Lin Y, Huang W, Wang X . Direct Reprograming of Mouse Fibroblasts into Dermal Papilla Cells via Small Molecules. Int J Mol Sci. 2022; 23(8). PMC: 9030401. DOI: 10.3390/ijms23084213. View

Wolk K, Wenzel J, Tsaousi A, Witte-Handel E, Babel N, Zelenak C . Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. Br J Dermatol. 2017; 177(5):1385-1393. DOI: 10.1111/bjd.15424. View

Brook I, Frazier E . Aerobic and anaerobic microbiology of axillary hidradenitis suppurativa. J Med Microbiol. 1999; 48(1):103-105. DOI: 10.1099/00222615-48-1-103. View

Cruciani M, Lipsky B, Mengoli C, de Lalla F . Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections?: A meta-analysis. Diabetes Care. 2005; 28(2):454-60. DOI: 10.2337/diacare.28.2.454. View

Krajewski P, Matusiak L, von Stebut E, Schultheis M, Kirschner U, Nikolakis G . Pain in Hidradenitis Suppurativa: A Cross-sectional Study of 1,795 Patients. Acta Derm Venereol. 2020; 101(1):adv00364. PMC: 9309859. DOI: 10.2340/00015555-3724. View

Kimball A, Okun M, Williams D, Gottlieb A, Papp K, Zouboulis C . Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016; 375(5):422-34. DOI: 10.1056/NEJMoa1504370. View

10.

Shi G, Sohn K, Li Z, Choi D, Park Y, Kim J . Expression and functional role of Sox9 in human epidermal keratinocytes. PLoS One. 2013; 8(1):e54355. PMC: 3548846. DOI: 10.1371/journal.pone.0054355. View

11.

Deng C, Hu Y, Zhu D, Cheng Q, Gu J, Feng Q . Single-cell RNA-seq reveals fibroblast heterogeneity and increased mesenchymal fibroblasts in human fibrotic skin diseases. Nat Commun. 2021; 12(1):3709. PMC: 8211847. DOI: 10.1038/s41467-021-24110-y. View

12.

Sur I, Rozell B, Jaks V, Bergstrom A, Toftgard R . Epidermal and craniofacial defects in mice overexpressing Klf5 in the basal layer of the epidermis. J Cell Sci. 2006; 119(Pt 17):3593-601. DOI: 10.1242/jcs.03070. View

13.

Bartoschek M, Oskolkov N, Bocci M, Lovrot J, Larsson C, Sommarin M . Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018; 9(1):5150. PMC: 6279758. DOI: 10.1038/s41467-018-07582-3. View

14.

Flora A, Jepsen R, Kozera E, Woods J, Cains G, Radzieta M . Human dermal fibroblast subpopulations and epithelial mesenchymal transition signals in hidradenitis suppurativa tunnels are normalized by spleen tyrosine kinase antagonism in vivo. PLoS One. 2023; 18(11):e0282763. PMC: 10624284. DOI: 10.1371/journal.pone.0282763. View

15.

Shishido-Takahashi N, Garcet S, Cueto I, Miura S, Li X, Rambhia D . Hepatocyte Growth Factor Has Unique Functions in Keratinocytes that Differ from those of IL-17A and TNF and May Contribute to Inflammatory Pathways in Hidradenitis Suppurativa. J Invest Dermatol. 2024; 145(3):536-547.e7. DOI: 10.1016/j.jid.2024.07.005. View

16.

Thorlacius L, Garg A, Riis P, Nielsen S, Bettoli V, Ingram J . Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa. Br J Dermatol. 2019; 181(3):483-491. DOI: 10.1111/bjd.17716. View

17.

Bechara F, Podda M, Prens E, Horvath B, Giamarellos-Bourboulis E, Alavi A . Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial. JAMA Surg. 2021; 156(11):1001-1009. PMC: 8374740. DOI: 10.1001/jamasurg.2021.3655. View

18.

Sun Q, Broadaway K, Edmiston S, Fajgenbaum K, Miller-Fleming T, Westerkam L . Genetic Variants Associated With Hidradenitis Suppurativa. JAMA Dermatol. 2023; 159(9):930-938. PMC: 10372759. DOI: 10.1001/jamadermatol.2023.2217. View

19.

Goodman W, Levine A, Massari J, Sugiyama H, McCormick T, Cooper K . IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol. 2009; 183(5):3170-6. PMC: 2903207. DOI: 10.4049/jimmunol.0803721. View

20.

Chen V, Burgess J, Verpile R, Tomic-Canic M, Pastar I . Novel Diagnostic Technologies and Therapeutic Approaches Targeting Chronic Wound Biofilms and Microbiota. Curr Dermatol Rep. 2023; 11(2):60-72. PMC: 10065746. DOI: 10.1007/s13671-022-00354-9. View